Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics Inc (NQ: CGTX )

2.790 +0.300 (+12.05%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cognition Therapeutics Inc

Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease
- First Human Evidence that CT1812 Selectively Engages Aβ Oligomers 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases
International Journal of Molecular Science Review Presents Mechanistic Rationale for Sigma-2 Receptor Modulation in Alzheimer’s Disease, Dementia with Lewy Bodies and Geographic Atrophy 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023
- CEO Participating on Panel Hosted by Alzheimer’s Drug Discovery Foundation - 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
Conference Call and Live Audio Webcast Scheduled for Thursday, March 23, 2023, 8:00 a.m. ET 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
Conference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ET 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
Innovative Trial Explores Theta Wave qEEG as a Biomarker of Synaptic Dysfunction 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"
From Cognition Therapeutics, Inc.
Via GlobeNewswire
First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812
SHINE Study Expanded from USA to Include sites in Spain, the Netherlands, and Czech Republic 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD
Innovative trial addresses second most common dementia after Alzheimer’s disease, now enrolling patients at up to 30 activated sites across the USA 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Closing of Public Offering
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Pricing of Public Offering
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.
Estimated Over 1.4 Million Americans Suffer from LBD – Often Misdiagnosed – No Approved Treatments 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.